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Cannabidiol restores intestinal barrier
dysfunction and inhibits the apoptotic
process induced by Clostridium difficile
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Abstract
Background: Clostridium difficile toxin A is responsible for colonic damage observed in infected patients. Drugs able to
restore Clostridium difficile toxin A-induced toxicity have the potential to improve the recovery of infected patients.
Cannabidiol is a non-psychotropic component of Cannabis sativa, which has been demonstrated to protect enterocytes
against chemical and/or inflammatory damage and to restore intestinal mucosa integrity.
Objective: The purpose of this study was to evaluate (a) the anti-apoptotic effect and (b) the mechanisms by which
cannabidiol protects mucosal integrity in Caco-2 cells exposed to Clostridium difficile toxin A.
Methods: Caco-2 cells were exposed to Clostridium difficile toxin A (30 ng/ml), with or without cannabidiol (107–109M), in
the presence of the specific antagonist AM251 (107M). Cytotoxicity assay, transepithelial electrical resistence measure-
ments, immunofluorescence analysis and immunoblot analysis were performed in the different experimental conditions.
Results: Clostridium difficile toxin A significantly decreased Caco-2 cells’ viability and reduced transepithelial electrical
resistence values and RhoA guanosine triphosphate (GTP), bax, zonula occludens-1 and occludin protein expression,
respectively. All these effects were significantly and concentration-dependently inhibited by cannabidiol, whose effects
were completely abolished in the presence of the cannabinoid receptor type 1 (CB1) antagonist, AM251.
Conclusions: Cannabidiol improved Clostridium difficile toxin A-induced damage in Caco-2 cells, by inhibiting the apoptotic
process and restoring the intestinal barrier integrity, through the involvement of the CB1 receptor.
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Introduction
Clostridium diﬃcile infection (CDI) is responsible for
the pseudomembranous colitis, a serious pathological
condition of the large intestine, characterised by mas-
sive inﬂammation and bleeding.1 It is known that
Clostridium diﬃcile produces two enterotoxins, named
Clostridium diﬃcile toxin A and B (TcdA and TcdB,
respectively) that, in turn, are responsible for the exten-
sive colonic mucosal damage, causing severe diarrhoea,
colitis, shock and death in most severe cases.2,3 TcdA is
the major cause of Clostridium diﬃcile enterotoxicity.
TcdA is a glucosyltransferase, that once internalised
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into the host cell via receptor-mediated endocytosis,
inactivates small GTPases.4 Among these proteins,
RhoA, a small GTPase member of the Rho subfamily
that is a critical regulator of actin cytoskeleton and
tight junction assembly, is the primary target of
TcdA.5 TcdA-induced inactivation of RhoA results in
the transition from guanosine triphosphate (GTP)-
bound form (active) to guanosine diphosphate
(GDP)-bound form (inactive), leading to an alteration
of cellular structure and tight junction integrity, and
consequently to increased epithelial barrier permeabil-
ity; this process is also sustained by the acute inﬂam-
mation of colonic mucosa and contributes to the leaky
gut and massive ions’ secretion.6 Due to its role in the
mucosal homeostasis and functions, the targeting of
RhoA may represent an innovative pharmacological
strategy for the treatment of CDI.
In the last decade, cannabinoids extracted from the
marijuana plant (Cannabis sativa) and synthetic canna-
binoids have shown numerous beneﬁcial eﬀects on
gastrointestinal (GI) functions.7 Non-psychotropic
phytocannabinoid cannabidiol (CBD) is one of the
most interesting compounds, since it exerts a wide
range of beneﬁcial pharmacological actions on GI func-
tions, ranging from antioxidant to antinﬂammatory
activities.8,9 Unlike psychoactive cannabinoids such as
tetrahydrocannabidiol (THC), CBD has little binding
aﬃnity to cannabinoid receptors (either CB1 and CB2);
whereas, by acting on peroxisome proliferator-acti-
vated receptor gamma (PPARg)10 and 5-hydroxytryp-
tamine (5HT)-1A receptors,11 it displays
antinﬂammatory and antioxidant eﬀects.12 Unlike
other phytocannabinoids, CBD has been shown to act
as a non-competitive negative allosteric modulator of
CB1 receptors.13 Notably, CBD is able to restore
in vitro intestinal permeability increased by ethylene-
diaminetetraacetic acid (EDTA) or pro-inﬂammatory
stimuli.14,15 So far, no evidence has been produced
about the putative protective role exerted by CBD in
CDI. To further this aim, the present study was
addressed at evaluating the in vitro eﬀects of CBD on
TcdA-induced apoptosis in Caco-2 cells and at investi-
gating the eﬀects of CBD and its mechanism of action.
Materials and methods
Materials
The experiments were performed in human Caucasian
colon adenocarcinoma (Caco-2) cells that have been
shown to be a good model to address TcdA toxicity
in vitro.16 Caco-2 cells were purchased from
European Collection of Cell Cultures (ECACC,
Public Health England, Porton Down, Salisbury,
UK). Cell medium, chemicals and reagents used for
cell culture, and TcdA were obtained from Sigma-
Aldrich (St. Louis, Missouri, USA). Instruments,
reagents, and materials used for Western blot analysis
were obtained from Bio-Rad Laboratories (Milan,
Italy). CBD and AM251 (CB1 receptor antagonist)
were purchased from Tocris Cookson, Inc. (Ballwin,
Missouri, USA). The antibodies rabbit anti-zonula
occludens-1 (ZO-1), rabbit anti-occludin, rabbit anti-
bax and rabbit anti-glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibodies were procured
from Cell Signalling Technology (Danvers,
Massachusetts, USA). Mouse anti-ZO-1 antibody was
purchased from Santa Cruz Biotechnology (Santa
Cruz, California, USA). Mouse monoclonal anti-
body anti-active RhoA by New East Bioscience
(Pennsylvania, USA) has been used. Fluorescein isothio-
cyanate-conjugated anti-rabbit antibody and Texas red
conjugated anti-mouse antibody were purchased from
Abcam (Cambridge, UK) and horseradish peroxidase
(HRP) was obtained from Dako (Milan, Italy).
Cell culture and experimental conditions
Caco-2 cells were grown at 37C with 5% CO2 in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) in
addition with 10% foetal bovine serum (FBS), 1%
penicillin–streptomycin, 2mM L-glutamate, and 1%
non-essential amino acids. Caco-2 cells were plated
at a density of 1 106 cells/well in six-well plates and
incubated for 24 h. Every 24–48 h the medium was
replaced with fresh medium to conﬂuence. After reach-
ing conﬂuence, the cells were washed three times
with phosphate-buﬀered saline (PBS), detached with
trypsin/EDTA, plated in six-well plates some contain-
ing and on polyethylene-terephtalate (PET) ﬁlter inserts
(Falcon Becton-Dickinson, 0.4mm pore diameter, area
4.21 cm2, pore density 2 0.2 106/cm2) to measure the
transepithelial electrical resistance (TEER), and
allowed to adhere for an appropriate time. Caco-2
cells were randomly divided into the following
groups: vehicle, 30 ng/ml TcdA, 30 ng/ml TcdA plus
CBD at 109, 108 and 107M CBD and 30 ng/ml
TcdA plus 107M CBD plus 107M CB1 receptor
antagonist AM251. The concentrations of CBD and
AM251 were selected on the basis of previous
reports14,15 and our preliminary experiments
(Supplementary Material, Figure 1, data not shown);
in brief, cells were treated with diﬀerent concentrations
of CBD and/or AM251 for 24 h and then incubated at
37C in the presence of TcdA for 24 h.
TEER
Caco-2 (TEER) was measured using the EVOM volt-
ohm meter (World Precision Instruments Germany,
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Berlin, Germany) according to the method described by
Wells and colleagues.17
In brief, cells were used for experimentation between
14–21 days and each epithelial cell layer with a TEER
value greater than 1000 cm2, was considered to have
tight adhesion. At this point, cell monolayers were trea-
ted according to experimental protocol described above
and TEER measurements were performed at diﬀerent
time points (2, 3, 5, 7, 12, 18 and 24 h, respectively).
TEER values were measured at a current of 20mA, cor-
rected for background, resistance value without cells,
and normalised bymultiplying the determined resistance
by eﬀective membrane growth area, 4.71 cm2.
TEER ð cm2Þ ¼ Total resistanceð
 blank resistanceÞ ð Þ Area cm2 
Cytotoxicity assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazo-
lium bromide (MTT) assay was used to determine
Caco-2 cell proliferation and survival.18 At least
(5 104 cells/well) were plated in 96-well plates and
allowed to adhere for 3 h. Then DMEM was replaced
with fresh medium and then cells were treated accord-
ing to the diﬀerent experimental protocols (see above).
After 24 h, 25 ml MTT (5mg/ml MTT in DMEM) was
added to the cells and the mixture was incubated for
further 3 h at 37C. Subsequently, the cells were lysed
and the dark blue crystals were solubilised using a
100 ml solution containing 50% N,N-dimethylforma-
mide and 20% (w/v) sodium dodecyl sulphate (SDS)
(pH 4.5). The optical density (OD) of each well was
determined using a microplate spectrophotometer
equipped with a 620 nm ﬁlter (PerkinElmer, Inc.;
Waltham, Massachusetts, USA).
Western blot analysis
Twenty-four hours after treatment, the cells (1 106/
well) were washed with ice-cold PBS, were harvested
into Separate Eppendorf tubes for diﬀerent treatment
groups and collected by centrifugation at 180 g for
10min at 4C. The cell pellet, obtained after centrifu-
gation, was re-suspended in 100 ml ice-cold hypotonic
lysis buﬀer (10mM 4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid (HEPES), 1.5mM MgCl2,
10mM KCl, 0.5mM phenylmethylsulphonylﬂuoride,
1.5 mg/ml soybean trypsin inhibitor, 7 mg/ml pepstatin
A, 5 mg/ml leupeptin, 0.1mM benzamidine and
0.5mM dithiothreitol (DTT)) and incubated on ice
for an additional 15min.
The suspension was rapidly passed through a syringe
needle ﬁve to six times to lyse the cells and then
centrifuged for 15min at 13,000 g to obtain the cyto-
plasmic fraction. The cytoplasmic fraction proteins
were used to determine the protein concentration with
Bradford assay and mixed with non-reducing gel load-
ing buﬀer (50mM Tris (hydroxymethyl) aminomethane
(Tris),10% SDS, 10% glycerol, 2mg bromophenol/ml)
at a 1:1 ratio. The solutions were then boiled for 3min,
centrifugated at 10,000 g for 10min and 50 mg of each
homogenate was used for electrophoresis using 12%
discontinuous polyacrylamide mini gels. Proteins were
then transferred to nitrocellulose membranes that were
saturated by incubation with 10% non-fat dry milk in
1X PBS overnight at 4C and then incubated with
rabbit anti-ZO-1 (1:1000), rabbit anti-occludin
(1:1000), mouse anti-active RhoA (1:1000), rabbit
anti-bax (1:1000) and rabbit anti-GAPDH (1:1000)
antibodies. After being extensively washed in TBS 1X
with 0.1% Tween 20, membranes were then incubated
for 2 h at room temperature with the speciﬁc secondary
antibodies conjugated to HRP anti-mouse (1:2000) or
anti-rabbit (1:3000). Immune complexes were identiﬁed
by enhanced chemiluminescence detection reagents
(Amersham Biosciences, Milan, Italy) and the blots
were analysed by scanning densitometry (GS-700
Imaging 143 Densitometer; Bio-Rad, Segrate, Italy).
Results are expressed as OD; (arbitrary units; mm2)
and normalised against the expression of the house-
keeping protein GAPDH.
Immunofluorescence
For these experiments, Caco-2 cells were cultured onto
coverslips until conﬂuence, and then treated according
to the diﬀerent above-described protocols. Cells were
then ﬁxed for 30min in 4% formaldehyde, washed
with ice-cold PBS and permeabilised with 0.3%
Triton-X100 in PBS for one hour. Subsequently, 2%
bovine serum albumin (BSA) was used to block the
nonspeciﬁc binding sites. The cells were then incu-
bated overnight with mouse anti-ZO-1 (1:100), or
rabbit anti-occludin antibody (1:100), following PBS
washing and further incubated in the dark for half
an hour with the appropriate secondary antibody
(ﬂuorescein isothiocyanate (FITC)-conjugated anti-
rabbit or Texas red conjugated anti-mouse). After
ﬁnal PBS washing, the cells were analysed using a
microscope (Nikon Eclipse 80i), and images were cap-
tured with a high-resolution digital camera (Nikon
Digital Sight DS-U1). Texas Red was excited at a
wavelength of 568 nm and collected through a long
pass ﬁlter (590LP). FITC was excited with a wave-
length of 488 nm and collected with a narrow band
ﬁlter (515–540BP). Texas Red and FITC were
assigned to the red and green channels respectively
of the generated RGB channel image.
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Statistical analysis
Results are expressed as mean standard error of the
mean (SEM) of four or ﬁve experiments and each
experiment was performed in triplicate. Statistical ana-
lysis was performed using parametric one-way analysis
of variance (ANOVA) and Bonferroni’s post-hoc test
was used for multiple comparisons. Values of p< 0.05
were considered signiﬁcant.
Results
CBD affects TcdA-induced damage of epithelial
barrier integrity and restores the expression of
ZO-1 and occludin
TEER measurements were performed to evaluate the
eﬀect of CBD (107, 108 and 109M) alone, or in
the presence of CB1 antagonist AM251, on epithelial
barrier integrity of Caco-2 cells layers exposed to TcdA
(30 ng/ml) for 24 h.
As shown in Figure 1(a), TcdA exposure induced a
signiﬁcant and time-dependent reduction of TEER (by
35, 46, 57, 69, 78, 81 and 86%, at 2, 3, 5, 7,
12, 18 and 24 h, respectively; p< 0.01 at 2 h and
p< 0.001 at all other time-points). Starting from 2h
after toxin challenge, the eﬀect of TcdA on electrical
resistance was signiﬁcantly and concentration-
dependently counteracted by CBD treatment
(Figure 1(a)); TEER values at 2, 3, 5, 7, 12, 18 and
24 h were indeed signiﬁcantly increased by 15, 33, 56,
73, 119, 133 and 225% in CBD 109M-treated cells
(p¼ns at 2 h and p< 0.01 at all other time-points),
while CBD 108M and CBD 107M treatments yield
to a signiﬁcant increase of TEER values by 31, 52, 90,
133, 219, 239, 361%, and 38, 65, 114, 193, 300, 372 and
538%, respectively (p< 0.01 at 2 and 3 h and p< 0.001
at all other time points for CBD 108M; p< 0.01 at
2, 3 and 5 h and p< 0.001 at all other time-points for
CBD 107M).
Interestingly, the eﬀect of CBD on the TcdA-
induced TEER reduction was completely abolished in
the presence of the CB1 antagonist, AM251 (p< 0.01,
Figure 1(a)).
Immunoﬂuorescence analysis, showed that 107M
CBD, markedly reversed the TcdA-induced decrease
of both occludin and ZO-1 co-expression in cultured
cells, thus restoring the epithelial barrier architecture
(Figure 1(b)). This ﬁnding was conﬁrmed by quantita-
tive analysis showing that TcdA-reduced expression of
occludin and ZO-1 (0.3 0.1 and 0.2 0.1 vs 1.0 0.1
fold-change in the vehicle group, respectively; all
p< 0.001) was signiﬁcantly and concentration depend-
ently restored by CBD at the doses of 109M (occludin:
2.1 0.2 vs 1.0 0.3 fold-change in TcdA-treated cells,
p< 0.01; ZO-1: 2.6 0.5 vs 1.0 0.5 fold-change in
TcdA-treated cells, p< 0.05), 108M (occludin:
2.6 0.3 vs 1.0 0.3 fold-change in TcdA-treated
cells, p< 0.001; ZO-1: 4.4 0.4 vs 1.0 0.5 fold-
change in TcdA-treated cells, p< 0.001) and 107M
(occludin: 3.1 0.3 vs 1.0 0.3 fold-change in TcdA-
treated cells, p< 0.001; ZO-1: 5.5 0.5 vs 1.0 0.5
fold-change in TcdA-treated cells, p< 0.001)
(Figure 1(c) and (d)). Once again, AM251 signiﬁcantly
inhibited the CBD-mediated rescue of ZO-1 and occlu-
din proteins (all p< 0.001) (Figure 1(b)–(d)).
CBD inhibits TcdA-induced apoptosis
and cells’ toxicity
As shown in Figure 2(a), a signiﬁcant decrease in Caco-
2 cell viability was observed at 24 h following the TcdA
challenge (70% as compared to vehicle group
assumed as 100% viable cells, p< 0.001). Under the
same experimental conditions, CBD caused a signiﬁ-
cant and concentration-dependent inhibition of
TcdA-induced cytotoxicity, resulting in an increased
cells’ viability (by 61, 133 and 328% at 109, 108
and 107M, respectively, vs TcdA group (p< 0.05,
p< 0.01 and p< 0.001, respectively).
Exposure to TcdA signiﬁcantly reduced the expres-
sion of RhoA GTP (0.2 0.1 vs 1.0 0.3 fold-change in
the vehicle group, p< 0.001) and increased the expres-
sion of the pro-apoptotic Bax protein (10.5 1.2 vs
1.0 0.5 fold-change in the vehicle group, p< 0.001)
(Figure 2(b) and (c)); these eﬀects were signiﬁcantly
restored by CBD, that at 109, 108 and 107M
increased the expression of RhoA GTP (1.8 0.4,
3.3 0.5 and 4.5 0.5 vs 1.0 0.3 fold-change in
TcdA-treated cells; p< 0.05, p< 0.001 and p< 0.001,
respectively) and decreased the expression of Bax
(0.7 0.1, 0.6 0.1 and 0.2 0.1 vs 1.0 0.1 fold-
change in TcdA-treated cells; p< 0.05, p< 0.001 and
p< 0.001) (Figure 2(b) and (c)). As shown for the
TcdA-impaired barrier function the protective eﬀects
of CBD on cells toxicity were completely abolished in
the presence of AM251 (all p< 0.001) (Figure 2(a)–(c)).
Discussion
CDI is one of the main causes of nosocomial diarrhoea
and it is responsible for pseudomembranous colitis. An
annual incidence of450,000 cases in the USA has
been estimated, turning CDI into a very important
sanitary emergency;19 since it is associated with signiﬁ-
cant morbidity, 5% infection-related mortality and an
overall mortality of 13–20%.3,20 There is an urgent
need for new drugs able to improve CDI outcome,
maximising the recovery of patients.
Due to its ability to inhibit Rho GTP activation,4,21
TcdA has been postulated as the main enterotoxin
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involved in gut mucosal disruption,5,22 leaky gut and
loss of cell-to-cell integrity, leading to massive apop-
tosis.23,24 The inhibition of TcdA eﬀects might thus
represent the key for a targeted therapy of CDI.
In this perspective, cannabinoids might display a
wide range of protective eﬀects on the GI epithelial
barrier, due to their antinﬂammatory, anticancer and
antioxidant properties.25,26 Among the almost 113
active phytocannabinoids isolated from Cannabis
sativa plant, CBD is one of the most interesting com-
pounds considered for medical use, as diﬀerent clinical
reports showed its almost complete lack of side eﬀects
in humans.27 Remarkably, CBD is a non-psychotropic
cannabinoid (unlike 9-THC) and does not interfere
with psychomotor learning and psychological
functions.28
In this study we have demonstrated, for the ﬁrst
time, that CBD is able to preserve mucosal integrity
and to reduce cellular permeability in in vitro cultured
Caco-2 cells, counteracting the eﬀects of TcdA. CBD,
indeed, caused a concentration-dependent increase of
transepithelial resistance, signiﬁcantly preventing the
enterotoxin-evoked damage. Moreover, CBD caused a
marked inhibition of cell death in TcdA-exposed cells,
due to a concentration-dependent up-regulation of
both occludin and ZO-1 protein, two of the main cell-
to-cell tight junction proteins.29 Furthermore, CBD
caused a signiﬁcant RhoA GTP rescue that raised in
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Figure 1. Effect of cannabidiol (CBD) on transepithelial electrical resistance (TEER) and barrier integrity of Clostridium difficile toxin A
(TcdA)-exposed Caco-2 cells. (a) 24 h Time course TEER changes following treatment (n¼ 4); (b) immunofluorescent staining showing the
effects of TcdA on zonula occludens-1 (ZO-1) and occludin co-expression at 24 h. Nuclei were stained by DAPI (scalebar¼ 25 mm);
(c) immunoreactive bands corresponding to ZO-1 and occludin expression at 24 h following the TcdA challenge; (d) relative densitometric
analysis of immunoreactive bands (arbitrary units normalised against the expression of the housekeeping glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) protein; n¼ 5). Results are expressed as mean standard error of the mean (SEM) of experiments performed in
triplicate. ***p< 0.001 and **p< 0.01 vs vehicle group; p< 0.001, p< 0.01 and p< 0.05 vs TcdA group. DAPI (4’,6-diamidino-2-
phenylindole).
Gigli et al. 5
parallel with the inhibition of pro-apoptotic Bax pro-
tein expression; these combined eﬀects likely account
for the restoration of the TcdA-induced intestinal bar-
rier dysfunction and apoptosis.
CBD eﬀects were, at least partially, mediated by crit-
ical involvement of the CB-1 receptor, since they were
almost completely abolished in the presence of the spe-
ciﬁc CB-1 receptor antagonist AM251.
Although diﬀerent receptors have been proposed to
mediate CBD activity,11,30 it has been postulated that
CBD may represent a non-competitive negative allo-
steric modulator of CB1 receptors.13 Consequently,
the presence of a speciﬁc CB1 antagonist markedly
impairs CBD activity, as previously demonstrated by
diﬀerent studies.14,15 Accordingly, CBD was able to
contain cellular damage in the in vitro model of muco-
sal disruption, as it occurs in our experimental condi-
tions. Our results indicated that CBD is able to increase
RhoA GTP expression, via the selective involvement of
CB-1 receptors. However, CBD exhibits both antioxi-
dant and antinﬂammatory properties, labelled as gen-
eric neuroprotective functions,30 mediated by a number
of diﬀerent pathways and cellular eﬀectors, that have
been only partially recognised so far. These so-called
‘entourage’ eﬀects are not to be excluded a priori when
considering the potential therapeutic eﬀects of this
compound in CDI.
One can speculate that this entourage activity might
synergistically cooperate with CB-1 dependent negative
allosteric modulation, further enhancing the protective
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Figure 2. Effect of cannabidiol (CBD) on Clostridium difficile toxin A (TcdA)-induced cells toxicity and apoptosis. (a) 3-[4,5-Dimethylthiazol-
2-yl]-2,5 diphenyltetrazolium bromide (MTT) cell viability absorbance at 24 h (n¼ 5); (b) immunoreactive bands corresponding to RhoA
GTP and Bax expression at 24 h following the TcdA challenge; (c) relative densitometric analysis of immunoreactive bands (arbitrary units
normalised against the expression of the housekeeping glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein; n¼ 5). Results are
expressed as mean standard error of the mean (SEM) of experiments performed in triplicate. ***p< 0.001 and vs vehicle group;
p< 0.001, p< 0.01 and p< 0.05 vs TcdA group. GTP: guanosine triphosphate.
6 United European Gastroenterology Journal 0(0)
eﬀects on gut epithelial cells; preventing the cytotoxic
eﬀects of reactive oxygen species products and pro-
inﬂammatory cytokines,31,32 released in the mucosa fol-
lowing TcdA stimulus.
In recent decades, CBD has been proposed as an
eﬀective therapeutic option in a variety of GI patholo-
gies, ranging from inﬂammatory bowel disease8 to
colon cancer,33 inﬂammatory hypermotility in mice34
and intestinal sepsis.35 The results of our preliminary
report indicate that CBD might be an intriguing candi-
date in CDI treatment, as well.
Although to be conﬁrmed in vivo, the multifa-
ceted activities exerted by CBD might prevent the cyto-
toxic damage in CDI and from a translational
standpoint, given its lack of any signiﬁcant toxic
eﬀect in humans, may ideally represent an eﬀective
adjuvant treatment in this high-mortality and morbid-
ity rate condition.
Conclusion
Clostridium diﬃcile infection is the leading cause of
hospital-acquired diarrhoea and pseudomembranous
colitis. Clostridium diﬃcile-Toxin A signiﬁcantly aﬀects
enterocytes permeability leading to apoptosis and colo-
nic mucosal damage. In the present study, we showed
that Cannabidiol, a non-psychotropic component of
Cannabis sativa signiﬁcantly inhibit the apoptosis rate
in TcdA-exposed cells and restores barrier function by
a signiﬁcant RhoA GTP rescue. We also provide evi-
dence that the eﬀects of Cannabidiol are mediated by
CB-1 receptor. Given the absence of any signiﬁcant
toxic eﬀect in humans, cannabidiol may ideally repre-
sent an eﬀective adjuvant treatment for Clostridium
diﬃcile-associated colitis.
Knowledge on this subject:
1. Clostridium diﬃcile infection is the leading cause of
hospital-acquired diarrhoea and pseudomembran-
ous colitis
2. Clostridium diﬃcile-Toxin A is responsible for
extensive colonic mucosal damage and altered bar-
rier function
3. Cannabidiol is a non-psychotropic component of
Cannabis sativa with potent anti-inﬂammatory activ-
ities on the gastrointestional tract
What are the signiﬁcant and/or new ﬁndings of this
study?
1. Clostridium diﬃcile-Toxin A signiﬁcantly aﬀects
enterocytes permeability and apoptosis
2. Cannabidiol caused a marked inhibition of apop-
tosis in TcdA-exposed cells and restores barrier func-
tion by a signiﬁcant RhoA GTP rescue
3. The protective eﬀects of Cannabidiol are mediated
by CB-1 receptor
4. Given the absence of any signiﬁcant toxic eﬀect in
humans, cannabidiol may ideally represent an eﬀect-
ive adjuvant treatment for Clostridium diﬃcile-asso-
ciated colitis
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